Exblifep® (cefepime/enmetazobactam) – New drug approval
February 22, 2024 - The FDA approved Allecra Therapeutics’ Exblifep (cefepime/ enmetazobactam), for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.
Top